P/E ratio for Clovis Oncology (CLVS)

P/E ratio history for Clovis Oncology from 2012 to 2022

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
BioMarin Pharmaceutical BMRN	91.7	-213,559.72%	🇺🇸 USA
AstraZeneca AZN	39.7	-92,617.05%	🇬🇧 UK
Pfizer PFE	15.9	-37,216.12%	🇺🇸 USA
Johnson & Johnson JNJ	11.7	-27,336.46%	🇺🇸 USA
AbbVie ABBV	52.6	-122,542.10%	🇺🇸 USA
Eli Lilly LLY	169	-392,386.39%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.